M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Atypical Endometrial Hyperplasia
Stage IB Uterine Corpus Cancer AJCC v7
Stage IA Uterine Corpus Cancer AJCC v7
Stage II Uterine Corpus Cancer AJCC v7
Stage I Uterine Corpus Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Device: Levonorgestrel-Releasing Intrauterine System
Other: Quality-of-Life Assessment

First Posted Date: 2008-11-11

Last Posted Date: 2024-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT00788671

Locations: 🇺🇸
MD Anderson League City, Nassau Bay, Texas, United States
🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 4 locations

Childhood Cancer Survivor Survey

Completed

Conditions: Cancer

Interventions: Other: Survey

First Posted Date: 2008-11-11

Last Posted Date: 2015-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 167

Registration Number: NCT00788476

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Zolinza (vorinostat)
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2008-11-07

Last Posted Date: 2014-09-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00787527

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: AZD6244
Drug: Dasatinib

First Posted Date: 2008-10-28

Last Posted Date: 2020-09-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 97

Registration Number: NCT00780676

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Clofarabine
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2008-10-23

Last Posted Date: 2016-07-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 122

Registration Number: NCT00778375

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Measuring Non-Enhancing Glioblastoma Progression

Completed

Conditions: Brain Tumor
Glioblastoma

Interventions: Procedure: MRI/MRS Scan

First Posted Date: 2008-10-22

Last Posted Date: 2012-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00777686

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lynne Cohen Consortium Project: Multi-Center Database/Registry

Completed

Conditions: Ovarian Cancer
Breast Cancer

Interventions: Other: Questionnaire

First Posted Date: 2008-10-22

Last Posted Date: 2014-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 176

Registration Number: NCT00776958

Locations: 🇺🇸
University of Alabama, Birmingham/Department of OB/GYN, Birmingham, Alabama, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Longitudinal Study of Symptoms in Colorectal Cancer

Terminated

Conditions: Colorectal Cancer

Interventions: Behavioral: Questionnaires

First Posted Date: 2008-10-22

Last Posted Date: 2019-05-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 509

Registration Number: NCT00777192

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy and Cardiac Enzymes

Completed

Conditions: Tumor

First Posted Date: 2008-10-22

Last Posted Date: 2018-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00777751

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab + Rituximab Consolidation in CLL

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Rituximab
Drug: Alemtuzumab

First Posted Date: 2008-10-13

Last Posted Date: 2015-06-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00771602

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy